GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Mpox global outbreak leads to significant increases in pharmaceutical stock markets
The WHO's mpox declaration led to significant stock market increases for pharmaceutical, medical tech, and biopharmaceutical companies, while airline stocks declined, reflecting investor concerns about mpox's global spread.
Why isn't medical advertising regulated like other advertising?
News media often repeat drug makers' medical claims as news, giving pharma companies free advertising and potentially misleading consumers. Examples include a shingles vaccine's alleged dementia risk reduction, GLP-1 agonists' mental health benefits, and Xolair's new urticaria treatment, all linked to conflicts of interest. Medical journals complicate conflict of interest identification, and news media rarely investigate the sources of these claims.
Asthma Biologics OK During Pregnancy if Patient Agrees, Consensus Statement Says
Biologic drugs for asthma can be used during conception, pregnancy, and breastfeeding with shared decision-making. Use should be recorded in registries, and restarting after birth is recommended if halted. Inactivated vaccinations for infants are safe even if mothers received biologics. Concerns remain due to limited clinical trial data, especially for newer biologics like tezepelumab.
GSK antibody drug reduces COPD attacks in trial
GSK's Nucala succeeded in a Phase 3 study for COPD patients with chronic bronchitis/emphysema, significantly reducing exacerbations. This follows a 2018 FDA rejection for lack of data. Nucala targets interleukin-5 and is already approved for severe asthma. GSK will discuss the new data with regulators and present it at a future medical meeting.
GSK announces positive results from phase III trial of Nucala (mepolizumab) in COPD
GSK announced positive results from the MATINEE phase III trial evaluating Nucala (mepolizumab) for COPD, showing a significant reduction in moderate/severe exacerbations. Nucala targets IL-5, key in type 2 inflammation, and is currently not indicated for COPD.
GSK Builds Nucala's COPD Case With Phase III Win
GSK announced positive Phase III MATINEE trial results for Nucala, showing a reduction in COPD exacerbations. Nucala, a monoclonal antibody targeting IL-5, is currently approved for severe asthma and other conditions but not COPD. GSK plans to present full trial findings and share results with health authorities. The COPD market is anticipating potential approvals for Sanofi and Regeneron's Dupixent and Verona's Ohtuvayre.
© Copyright 2024. All Rights Reserved by MedPath